NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company specializing in host-mimetic nanomedicine technology, has entered into a securities purchase agreement with a single institutional investor for a registered direct offering. The offering is expected to generate approximately $2 million in gross proceeds through the sale of 1,333,334 common shares, or pre-funded warrants in lieu thereof, along with accompanying warrants to purchase an equal number of common shares. The accompanying warrants carry an exercise price of $1.75 per share and a three-year term, with closing anticipated on or about May 18, 2026, subject to customary conditions. This capital raise is pivotal for NanoViricides as it continues to advance its lead antiviral candidate, NV-387, which targets a broad spectrum of respiratory viral illnesses.
The timing of this offering aligns with NanoViricides' strategic focus on NV-387, a revolutionary broad-spectrum antiviral that has received Orphan Drug Designation (ODD) from the U.S. FDA Office of Orphan Products Development. ODD status provides potential benefits including seven years of market exclusivity upon approval, tax credits for clinical trial costs, and fee exemptions. NV-387 has demonstrated efficacy in lethal animal infection models for influenza, RSV, coronaviruses, monkeypox, smallpox, and measles, positioning it as a potential first-line treatment for patients presenting with respiratory viral illnesses. The proceeds from this offering are expected to support ongoing clinical development and manufacturing efforts.
NanoViricides' technology is based on a host-mimetic approach that viruses and their variants cannot easily escape, offering a unique advantage in the fight against emerging viral threats. The company's platform is designed to create broad-spectrum antivirals that can be deployed rapidly, addressing a critical unmet need in pandemic preparedness. The offering was announced via a press release, which can be accessed at https://ibn.fm/Z8Etj.
Investors seeking the latest updates on NanoViricides can visit the company's newsroom at https://ibn.fm/NNVC. The offering underscores the company's commitment to advancing its pipeline and leveraging its proprietary nanomedicine technology to address global health challenges.
